Natco Joins Gilead’s Pact With Indian Companies for Sovaldi
This article is for subscribers only.
Natco Pharma Ltd., the Indian drugmaker that had challenged Gilead Sciences Inc.’s patent claims on a blockbuster hepatitis C treatment in the Asian country, said it signed a licensing agreement with the U.S. company for the drug.
The agreement allows Natco to manufacture and sell generic versions of Sovaldi and combination therapies using the active ingredient in the medicine in 91 developing countries, the Indian company said in a statement today.